Clin i cal Tri als.gov is a web -based re source which pro vides the gen eral pub lic, health care pro fes sion als, patients, and care givers ac cess to pri vately and pub licly sup ported clin i cal tri als and trial re sults. The web site is main tained by the Na tional Li brary of Med i cine (NLM) at the Na tional In sti tutes of Health (NIH) (Clin i cal Trials.gov Back ground, 2018). The penal ties for non -compliance with the le gal oblig a tions un der FDAAA 801 (Food and Drug Ad min is tra tion Amend ments Act of 2007) and the NIH re quire ments for reg is ter ing and report ing re sults on stud ies within cer tain time frames can re sult in large mon e tary fines and the with hold ing of fed eral funds (Clin i cal Tri als.gov FDAAA 801 and the Fi nal Rule, 2019). Years fol low ing, in 2016, the Fi nal Rule ex panded upon the re quire ment with ad di tional data el e ments for both reg is tra tion and re sult sub mis sion records in ac cor dance of FDAAA 801 (Clin i cal Tri als.gov FDAAA 801 and the Fi nal Rule, 2019).
. Introduction
Clin i cal Tri als.gov is a web -based re source man aged by the National In sti tutes of Health (NIH) and the Na tional Li brary of Med i cine. This pub lic web site, orig i nally launched in 2000, pro vides the gen eral pub lic, health care pro fes sion als, pa tients, and care givers ac cess to pri vately and pub licly sup ported clin i cal tri als [ 1 ] . The reg istry was cre ated as a re sult of the Food and Drug Ad min is tra tion Mod ern ization Act of 1997 (FDAMA 113), a law passed by Con gress that required the NIH to cre ate a pub lic in for ma tion re source on tri als reg ulated by the FDA in clud ing those which in volved In ves ti ga tional New Drug tri als for se ri ous or life threat en ing dis eases. The in tent of FDAMA 113 was to pro vide more trans parency of re search con ducted, as well as pro vid ing ac ces si bil ity to the pub lic ClinicalTrials. gov [ 2 ] . Adop tion of these oblig a tions was slow; a mere 1255 tri als were reg istered within the first year af ter launch of the web site in 2000 [ 3 ] .
The num ber of tri als reg is tered in ClinicalTrials. gov markedly increased in 2005 af ter the im ple men ta tion of the In ter na tional Commit tee of Med ical Jour nal Ed i tors (ICMJE) pol icy that re quired stud ies to be reg is tered in or der to be con sid ered for pub li ca tion [ 4 ] . In ad dition, Con gress passed FDAAA (Food and Drug Ad min is tra tion Amendments ACT) in 2007, which ul ti mately ex panded the types of stud ies re quir ing reg is tra tion, and the sub mis sion of a re sults record [ 5 ] .
Re ported com pli ance with the man date has been gen er ally poor [ 6 ] and when re sults re port ing re quire ments are ful filled, they are often times not done so within man dated time frames [ 7 ] . The de f i n i tion of com pli ance varies as there are sev eral oblig a tions and tim ing require ments for both reg is tra tion, on go ing record main te nance and results re port ing. A re cent analy sis of reg is tered clin i cal tri als re ported only 13% com pli ance with timely re port ing of data (An der son et al., 2015) . Fail ure to meet the oblig a tions of the FDAAA pre vents achievement of the over all goal of the man date, to im prove trans parency regard ing clin i cal tri als, but also risks sub stan tial fi nan cial penalty, up to $12,103 per day [ 8 ] and loss of NIH fund ing [ 9 ] .
The Med ical Uni ver sity of South Car olina (MUSC), along with the in sti tu tion's Of fice of Clin i cal Re search and Reg u la tory Knowl edge & Sup port group es tab lished a goal of full ad her ence to the reg is tra tion and re port ing oblig a tions of FDAAA and the re quire ments of the NIH Pol icy on the Dis sem i na tion of NIH funded Clin i cal Tri als. Hav ing the in fra struc ture in place to ed u cate our re searchers and pro vide the tools needed to en sure com pli ance with ClinicalTrials. gov is in alignment with the mis sion and ob jec tives of the site's Clin i cal & Trans lation Sci ence Award (CTSA) award. The CTSA pro gram is in tended to de velop in no v a tive so lu tions that will im prove the ef fi ciency, qual ity and im pact of re search [ 10 ] . His tor i cally, our in sti tu tion en trusted com pli ance with these re quire ments to the in di vid ual in ves ti ga tor, but it has since rec og nized that ad di tional sup port is nec es sary to achieve and main tain com pli ance. Through strate gic plan ning, our in tent was to de velop and im ple ment mul ti ple work flows for the var i ous facets of en ter ing data into ClinicalTrials. gov , in clud ing study reg is tra tion, record main te nance and re sults re port ing to achieve this goal. Here, we de scribe the ClinicalTrials. gov Com pli ance As sess ment Process, a mech a nism that iden ti fies stud ies re quir ing reg is tra tion un der our insti tu tion's Pro to col Reg is tra tion Sys tem (PRS) ac count, as well as other ser vices im ple mented to im prove com pli ance with the study reg is tra tion and re sults re port ing.
. Methods

1 . Assembling the team
The Reg u la tory Knowl edge & Sup port (RKS) pro gram of the South Car olina Clin i cal & Trans la tional Re search In sti tute (SCTR), with an aca d e mic home at the Med ical Uni ver sity of South Car olina (MUSC), de vel oped and im ple mented a plan to re solve our in sti tu tion's low com pli ance rate in re port ing. The process be gan with an au dit of all of MUSC's ClinicalTrials. gov records per formed by the RKS core un der the di rec tion of the As so ci ate Provost for Re search Com pli ance and Reg u la tory Af fairs. A full -time ClinicalTrials. gov co or di na tor was iden ti fied who was des ig nated as the in sti tu tion's pri mary PRS ad minis tra tor and tasked with over see ing in sti tu tional ef forts to achieve and main tain com pli ance. Mul ti ple av enues of train ing in clud ing uti lization of on line re sources and at ten dance at an in -person 2 -day com prehen sive Train the Trainer work shop con ducted at the NIH. Within six months, the co or di na tor was able to demon strate suf fi cient mas tery of the process and be gan man ag ing the PRS and con duct ing con sul tations in de pen dently. In ad di tion, our site par tic i pated in monthly meet ings with the ClinicalTrials. gov Task force, a na tion wide net work of CTSA mem bers, uni ver si ties, med ical cen ters, and non profit or ga niza tions that col lab o rate and share processes and ap proaches re gard ing ClinicalTrials. gov and the Pro to col Reg is tra tion Sys tem (PRS) [ 11 ] .
2 . Phase I: identifying noncompliant trials
We per formed an au dit of our in sti tu tion's base line com pli ance with re port ing of data for reg is tered tri als us ing both the pub lic -facing in ter face and in ter nal PRS ac counts. We iden ti fied du pli cate stud ies, as well as stud ies en tered in er ror, which were ad min is tra tively with -drawn af ter con sul ta tion with ClinicalTrials. gov re view ers. The in vesti ga tors of sev eral tri als had left the in sti tu tion with out del e gat ing respon si bil ity to an other to as sume record main te nance or re sultsreporting du ties; these re spon si bil i ties were then as signed to the respec tive de part ment chairs. In -depth re view of records yielded is sues that could have been pre vented at the start of record reg is tra tion, such as the de scrip tion of out come mea sures in a way that could not be un der stood dur ing the re sults sub mis sion process, thus re sult ing in more PRS re viewer com ments. We cat e go rized stud ies ac cord ing to their non -compliant sta tus and es tab lished pri or i ties based on the type of prob lem record and time elapsed rel a tive to the re port ing re quirement. Our high est pri or ity was to ad dress com pleted stud ies with results more than one year past due fol lowed by those that had not been up dated in 12 months, or had an an tic i pated start date in the past.
3 . Phase 2: implementing the ClinicalTrials. gov compliance assessment process
Fol low ing the com pli ance au dit, a memo from the As so ci ate Provost was sent via email to the en tire re search com mu nity at MUSC re it er at ing the im por tance of ClinicalTrials. gov com pli ance and inform ing them that a pro ject to im prove the in sti tu tion's com pli ance rate was un der way. In ves ti ga tors with stud ies deemed out of re porting com pli ance (Phase 1) were then sent a cus tomized email iden ti fying spe cific stud ies re quir ing at ten tion, how to ad dress the out standing is sues, and where to find the re sources if as sis tance was needed. All cor re spon dence was signed by lead er ship (As so ci ate Provost), with copies sent to the re spec tive de part ment chairs. In ves ti ga tors could request a con sul ta tion for ad vice and as sis tance with ClinicalTrials. gov nav i ga tion through SPAR CRe quest©, an open -source re search ser vices re quest and track ing sys tem de vel oped at MUSC [ 12 ] . SPAR CRe -quest© also serves as a repos i tory for shared rel e vant study doc uments (pro to col, in formed con sent doc u ments) and a cen tral ized system for com mu ni cat ing with study teams. We pro vided ad di tional train ing to the re search com mu nity through a va ri ety of for mats, includ ing Lunch and Learns and one -on -one con sul ta tions.
The MUSC ClinicalTrials. gov co or di na tor po si tion served as the pri mary re source for in ves ti ga tor train ing and con sul ta tion and de veloped stan dard op er at ing pro ce dures. This po si tion was housed in MUSC's Of fice of Clin i cal Re search (OCR), fa cil i tat ing col lab o ra tion with the var i ous re search sup port de part ments within the OCR. To reduce in ves ti ga tor bur den, en sure re view of all clin i cal re search studies, and min i mize the im pact on study start -up, the ClinicalTrials. gov com pli ance as sess ment process was in cor po rated into the es tab lished study billing com pli ance re view for all hu man sub ject re search stud ies at MUSC.
Dur ing the ClinicalTrials. gov com pli ance as sess ment, the ClinicalTrials. gov co or di na tor re viewed study doc u ments to de ter mine the Re spon si ble Party. The Re spon si ble Party is the en tity that reg isters the study, and sub mits re sults in for ma tion. It could be ei ther the spon sor of the trial, or the prin ci pal in ves ti ga tor des ig nated by the spon sor, grantee, con trac tor, or awardee [ 13 ] . When it was de termined that the MUSC or the MUSC Pri mary In ves ti ga tor was the Respon si ble Party the ClinicalTrials. gov co or di na tor would no tify the study team of po ten tial reg is ter ing re quire ments. A RED Cap® database was de vel oped to doc u ment the re view, in di cat ing whether the MUSC pri mary in ves ti ga tor or an other in sti tu tion was re spon si ble for reg is ter ing. Vol un tary reg is tra tion was some times en cour aged be cause it could be nec es sary for pub li ca tion pur poses. For study teams needing fur ther as sis tance with the reg is tra tion process, the ClinicalTrials. gov co or di na tor ini ti ated a record in ClinicalTrials. gov with ba sic study in for ma tion, such as the unique pro to col ID #, of fi cial study title, and study type. How ever, it was the re spon si bil ity of pri mary inves ti ga tor to com plete the record, main tain it through the life of the study, and re port re sults as re quired by fed eral law.
4 . Training and consultative resources
When it was de ter mined the re spon si ble party of the study was an MUSC in ves ti ga tor and ClinicalTrials. gov reg is tra tion was nec es sary, in ves ti ga tors were of fered one -on -one con sul ta tions. The ClinicalTrials. gov co or di na tor pro vided a brief back ground of the process, is sued lo gins for new users at tend ing the con sult, and nav igated through the var i ous re quired sec tions of a record while en ter ing study -specific in for ma tion.
Con sul ta tive ser vices are of fered as a re sult of the com pli ance assess ment but also to study team mem bers who have been tak ing on the re spon si bil ity of record main te nance and the task of re sults re porting.
5 . Escalation procedures
The Clinicaltrials. gov co or di na tor com mu ni cates reg u larly with study teams when up dates are re quired within a spe cific record, in par tic u lar when a re sults record due date is ap proach ing. If a study team is non -responsive, the Clinicaltrials. gov co or di na tor will in clude the As so ci ate Provost for Re search Com pli ance and Reg u la tory Af fairs on email com mu ni ca tions for ad di tional sup port. If needed, the depart ment chair will be in cluded in all cor re spon dence un til the record up date has been com pleted.
. Results
Phase 1: The com pli ance au dit was con ducted in Jan u ary 2018. MUSC was deemed the re spon si ble party for 493 study records. Results re vealed 403/ 493 (81.74%) non com pli ant records led by in ves tiga tors across var i ous de part ments at MUSC, who were then no ti fied of their oblig a tions and en cour aged to con sult with the ClinicalTrials. gov co or di na tor. The re main ing 90/ 493 records were iden ti fied as currently com pli ant, and 36/ 493 reg is tered stud ies were ad min is tra tively with drawn be cause of du pli ca tion or er ror. Of the in ves ti ga tors with non -compliant records, 23 sought con sul ta tion. Anec do tally, postconsultation feed back was gen er ally fa vor able. In ves ti ga tors in di cated that they val ued the as sis tance as they strug gled with the web site used for the reg is tra tion and re port ing [ 14 ] . The com pli ance rate improved rapidly ( Fig. 1 ) , and within 15 months, re sulted in an over all com pli ance rate of 98.6%, an in crease from the 18.26% com pli ance rate iden ti fied be fore the au dit be gan.
Phase 2 : With com pli ance of reg is tered stud ies well un der way, focus then shifted to im ple ment ing the ClinicalTrials. gov Com pli ance As sess ment work flow with the pur pose of re view ing and iden ti fy ing those tri als re quir ing ini tial reg is tra tion. Since in te grat ing our par al lel process along with the OCR billing com pli ance re view, 367 tri als have un der gone a ClinicalTrials. gov com pli ance as sess ment and 31/ 367 trials (8.45%) were MUSC In ves ti ga tor Ini ti ated and re quired reg is tration un der the MUSC PRS ac count. Of those re quir ing ini tial reg is tration nearly half (45%) of pri mary in ves ti ga tors or their de signee utilized the train ing and con sul ta tive ser vices that we pro vide.
As rou tine record main te nance was con tin u ously per formed, the es ca la tion pro ce dures were found to be help ful when prob lem records were iden ti fied. When lead er ship, or a de part ment chair was in cluded in cor re spon dence, we found study teams re sponded quickly and the record was brought back into com pli ance.
. Discussion
The re search com mu nity has an in her ent, eth i cal re spon si bil ity to en sure trans parency with the pub lic. This is im por tant not only to facil i tate ac cess of clin i cal trial in for ma tion for the pub lic for study enroll ment, but also to make avail able ac cu rate and com plete study results, be it pos i tive, neg a tive or in con clu sive re sults. Con sis tent with what has been re ported else where, our in ves ti ga tors found meet ing the re quire ments of ClinicialTrials. gov re port ing to be chal leng ing, result ing in a low over all base line com pli ance rate. Nonethe less, ad herence to the fed eral reg u la tions is also crit i cal. Fail ing to do so may not only re sult in civil and/ or fi nan cial penalty, but may also im pact grant fund ing as well as ham per the abil ity to pub lish find ings. With an ef fi cient work flow in place, we are not only ful fill ing our re spon sibil ity to the pub lic, but we are also pro vid ing the re search com mu nity at MUSC the re sources needed nec es sary while they are con duct ing re search at our in sti tu tion and be yond.
We rec og nized that in ves ti ga tors would need more than a reminder of their oblig a tions, and to gether with our Reg u la tory Knowledge and Sup port Pro gram, de vel oped a highly col lab o ra tive con sul tation and sup port ser vice that was ul ti mately in te grated within the exist ing OCR work flow. Prior to reach ing out to in ves ti ga tors, we system at i cally planned an ap proach to clearly iden tify the non -compliant records and es tab lish pri or i ties to achieve our goal of to tal com pli ance as ef fi ciently as pos si ble. Email com mu ni ca tion from lead er ship was an ef fec tive ap proach. While we strived for 100% com pli ance, we could not fore see the in di vid ual chal lenges of each prob lem record. We then sought to ad vise and sup port the study teams ac cord ingly. As a re sult of this strat egy, the num ber of prob lem records un der the MUSC PRS be gan to de crease.
Mov ing stud ies that were delin quent in re port ing into com pli ance was the first ma jor task, but our long -term aim is to sus tain this level of com pli ance through con tin ued mon i tor ing and out reach by proactively iden ti fy ing the stud ies re quir ing reg is tra tion and work ing with the study teams to com plete the records in an ac cu rate and timely man ner. In cor po rat ing the ClinicalTrials. gov com pli ance as sess ment process into the es tab lished OCR work flow en sures that all hu man sub ject stud ies at MUSC re ceive re view with out neg a tively af fect ing study start -up times. Of fer ing con sul ta tions and con sis tent com mu nica tion with the re search com mu nity will also help us meet our longterm goal of main tain ing high com pli ance. Pro mot ing aware ness of these processes is an im por tant as pect of the pro gram. We now track stud ies and send re port ing no ti fi ca tions 90, 60, and 30 days be fore ap plic a ble due dates, es ca lat ing via re search lead er ship when nec essary. The no ti fi ca tions in clude links to train ing in for ma tion and resources.
In con clu sion, mul ti ple lessons have been learned from this ef fort that may be in struc tive to other in sti tu tions who strug gle with this same is sue. First, a cen tral ized, in sti tu tional ap proach was the most ef fi cient man ner for MUSC to en sure suc cess with ClinicalTrials. gov reg is tra tion and re port ing re quire ments. Sec ond, it is a vi tal to have a work flow in place to de ter mine if a study needs to be reg is tered by an MUSC in ves ti ga tor be fore the study be gins en roll ment in or der to meet fed eral re quire ments, pub lish ing ex pec ta tions. Ad di tion ally, this en sures the pub lic has in for ma tional ac cess to clin i cal tri als con ducted at our site. Third, in ves ti ga tors have ben e fited from spe cific con sul tation, par tic u larly re lated to best prac tice rec om men da tions to cite clear and con cise out come mea sures re quired for reg is tra tion to min imize later re sults re port ing com pli ca tions. Over all this multi -faceted, prac ti cal ap proach can be ef fec tive when en sur ing com pli ance with trial re port ing and re sults sub mis sions, and ul ti mately achieves the over ar ch ing pur pose of trans parency and eth i cal oblig a tions as sumed by the re search com mu nity.
